Effect of sub-anaesthetic doses of ketamine in the postoperative period in a patient with uncontrolled depression;Efecto antidepresivo de dosis subanestésicas de ketamina en el postoperatorio de una paciente con depresión no controlada

Revista Espanola de Anestesiologia y Reanimacion

Volumn 60, Issue 2, 2013, Pages 110-113

  Cortinas Saenz M ^a,b   Alonso Menoyo, M B ^a,b   Errando Oyonarte, C L ^a,b   Alferez Garcia I ^a,b   Carricondo Martinez M A ^a,b  

^a Hospital Torreca and oacute rdenas   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

Author keywords

Ketamine; N methyl D aspartate receptor antagonists; Pain; Treatment resistant major depression

Indexed keywords

AMINO ACID RECEPTOR BLOCKING AGENT; ANALGESIC AGENT; ANTIDEPRESSANT AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ADENOCARCINOMA; ARTICLE; BONE TUMOR; BREAST TUMOR; CASE REPORT; DEPRESSION; DRUG ANTAGONISM; DRUG INTERACTION; DRUG RESISTANCE; FEMALE; HUMAN; MASTECTOMY; METASTASIS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEURALGIA; PILONIDAL SINUS; POSTOPERATIVE PAIN; PSYCHOLOGICAL ASPECT;

ADENOCARCINOMA; ANALGESICS; ANTIDEPRESSIVE AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; BONE NEOPLASMS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DEPRESSIVE DISORDER; DRUG INTERACTIONS; DRUG RESISTANCE; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HUMANS; KETAMINE; MASTECTOMY; MIDDLE AGED; NEURALGIA; PAIN, POSTOPERATIVE; PILONIDAL SINUS; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84880430527     PISSN: 00349356     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redar.2012.06.004     Document Type: Article

References (18)

1. Jadoon N.A., Munir W., Shahzad M.A., Choudhry Z.S. Assessment of depression and anxiety in adult cancer outpatients: a cross-sectional study. BMC Cancer 2010, 10:594-601.
2. Domino E.F. Taming the ketamine tiger. Anesthesiology 2010, 113:678-686.
3. Bell R, Eccleston C, Kalso E. Ketamina como coadyuvante de los opiáceos para el dolor del cáncer (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2008 Número 4. Oxford: Update Software Ltd. Disponible en: http://www.update-software.com [consultado 7 Jul 2012]. (Traducida de The Cochrane Library, 2008 Issue 3. Chichester, UK: John Wiley & Sons, Ltd.).
4. Stefanczyk-Sapieha L., Oneschuk D., Demas M. Intravenous ketamine " burst" for refractory depression in a patient with advanced cancer. J Palliat Med 2008, 11:1268-1271.
5. Depression: management of depression in primary and secondary care- NICE guidance. 2004 [consultado 7 Jul 2012]. Disponible en: http://www.nice.org.uk/nicemedia/pdf/CG023NICEguideline.pdf.
6. Hays R.D., Stewart A.L. Sleep measures. Measuring functioning and Well-Being 1992, 235-239. Duke University Press, Durham, NC. A.L. Stewart, J.E. Ware (Eds.).
7. Furuhashi-Yonaha A., Lida H., Asano T., Takeda T., Dohi S. Short- and long- term efficacy of oral ketamine in eight chronic-pain patients. Can J Anesth 2002, 49:886-887.
8. Kannan T.R., Saxena A., Bhatnagar S., Barry A. Oral ketamine as an adjuvant to oral morphine for neuropathic pain in cancer patients. J Pain Symptom Manage 2002, 23:60-65.
9. Arnold L., Leon T., Whalen E., Jeannette Barrett J. Relationships among pain and depressive and anxiety symptoms in clinical trials of pregabalin in fibromyalgia. Psychosomatics 2010, 51:489-497.
10. Boyce-Rustav J.M., Holmes A. Ethanol-related behaviors in mice lacking the NMDA receptor NR2A subunit. Psychopharmacology 2006, 187:455-466.
11. Sanacora G., Zarate C.A., Krystal J.H., Manji H.K. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov 2008, 7:426-437.
12. Machado-Vieira R., Salvadore G., Diazgranados N., Zarate C.A. Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacol Ther 2009, 123:143-150.
13. Karasawa J., Shimazaki T., Kawashima N., Chaki S. AMPA receptor stimulation mediates the antidepressant-like effect of a group II metabotropic glutamate receptor antagonist. Brain Res 2005, 1042:92-98.
14. Matrisciano F., Scaccianoce S., del Bianco P., Panaccione I., Canudas A.M., Battaglia G., et al. Metabotropic glutamate receptors and neuroadaptation to antidepressants: imipramine-induced down-regulation of beta-adrenergic receptors in mice treated with metabotropic glutamate 2/3 receptor ligands. J Neurochem 2005, 93:1345-1352.
15. Thase M.E. Treating major depression: antidepressant algorithms. J Clin Psychiatry 2009, 70:e46.
16. Trivedi M.H. Tools and strategies for ongoing assessment of depression: a measurement-based approach to remission. J Clin Psychiatry 2009, 70:26-31.
17. Collado A., Conesa A. Tratamiento farmacológico de la fibromialgia: hacia la neuromodulación química. Reumatol Clin 2009, 5:27-31.
18. Berman R.M., Cappiello A., Anand A., Oren D.A., Heninger G.R., Charney D.S., et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000, 47:351-354.